OCT4: A sensitive and specific immunohistochemical marker for metastatic germ cell tumors

Advances in Anatomic Pathology

Volumn 13, Issue 2, 2006, Pages 76-79

  Lau, Sean K ^a   Chang, Karen L ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Germ cell tumor; Immunohistochemistry; OCT4; Transcription factor

Indexed keywords

BIOLOGICAL MARKER; OCTAMER TRANSCRIPTION FACTOR 4; MONOCLONAL ANTIBODY; OKT4A; TUMOR MARKER;

ADOLESCENT; ADULT; CONTROLLED STUDY; EMBRYONAL CARCINOMA; GERM CELL TUMOR; GONAD TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; REVIEW; SEMINOMA; ARTICLE; CHORIOCARCINOMA; DIFFERENTIAL DIAGNOSIS; EVALUATION; METABOLISM; NEOPLASM; NEUROECTODERM TUMOR; TERATOMA; TESTIS TUMOR;

ANTIBODIES, MONOCLONAL; CARCINOMA, EMBRYONAL; CHORIOCARCINOMA; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOPLASMS, UNKNOWN PRIMARY; NEUROECTODERMAL TUMORS; SEMINOMA; TERATOMA; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33746880715     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/01.pap.0000213011.33232.72     Document Type: Review

References (28)

1. Okamoto K, Okazawa H, Okuda A, et al. A novel octamer binding transcription factor is differentially expressed in mouse embryonic cells. Cell. 1990;60:461-472.
2. Rosner MH, Vigano MA, Ozato K, et al. A POU-domain transcription factor in early stem cells and germ cells of the mammalian embryo. Nature. 1990;345:686-692.
3. Scholer HR, Ruppert S, Suzuki N, et al. New type of POU domain in germ line-specific protein Oct-4. Nature. 1990;344:435-439.
4. Pesce M, Scholer HR. Oct-4: control of totipotency and germline determination. Mol Reprod Dev. 2000;55:452-457.
5. Scholer HR, Dressler GR, Balling R, et al. Oct-4: a germline-specific transcription factor mapping to the mouse t-complex. EMBO J. 1990;9:2185-2195.
6. Pesce M, Scholer HR. Oct-4: gatekeeper in the beginnings of mammalian development. Stem Cells. 2001;19:271-278.
7. Nichols J, Zevnik B, Anastassiadis K, et al. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell. 1998;95:379-391.
8. Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet. 2000;24:372-376.
9. Looijenga LH, Stoop H, de Leeuw HP, et al. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res. 2003;63:2244-2250.
10. Gidekel S, Pizov G, Bergman Y, et al. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell. 2003;4:361-370.
11. Jones TD, Ulbright TM, Eble JN, et al. OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma. Am J Surg Pathol. 2004;28:935-940.
12. Cheng L, Thomas A, Roth LM, et al. OCT4: a novel biomarker for dysgerminoma of the ovary. Am J Surg Pathol. 2004;28:1341-1346.
13. Jones TD, Ulbright TM, Eble JN, et al. OCT4: A sensitive and specific biomarker for intratubular germ cell neoplasia of the testis. Clin Cancer Res. 2004;10:8544-8547.
14. Hattab EM, Tu PH, Wilson JD, et al. OCT4 immunohistochemistry is superior to placental alkaline phosphatase (PLAP) in the diagnosis of central nervous system germinoma. Am J Surg Pathol. 2005;29:368-371.
15. de Jong J, Stoop H, Dohle GR, et al. Diagnostic value of OCT3/4 for pre-invasive and invasive testicular germ cell tumours. J Pathol. 2005;206:242-249.
16. Cheng L. Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. Cancer. 2004;101:2006-2010.
17. Pavlidis N, Briasoulis E, Hainsworth J, et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39:1990-2005.
18. Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer. 2004;100:1776-1785.
19. Sporn JR, Greenberg BR. Empiric chemotherapy in patients with carcinoma of unknown primary site. Am J Med. 1990;88:49-55.
20. Hainsworth JD, Greco FA. Poorly differentiated carcinoma and germ cell tumors. Hematol Oncol Clin North Am. 1991;5:1223-1231.
21. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol. 1990;8:1777-1781.
22. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med. 1997;337:242-253.
23. Wick MR, Swanson PE, Manivel JC. Placental-like alkaline phosphatase reactivity in human tumors: an immunohistochemical study of 520 cases. Hum Pathol. 1987;18:946-954.
24. Hamilton-Dutoit SJ, Lou H, Pallesen G. The expression of placental alkaline phosphatase (PLAP) and PLAP-like enzymes in normal and neoplastic human tissues. An immunohistological survey using monoclonal antibodies. APMIS. 1990;98:797-811.
25. Arber DA, Tamayo R, Weiss LM. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol. 1998;29:498-504.
26. Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol. 2005;13:205-220.
27. Schwarting R, Gerdes J, Durkop H, et al. BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood. 1989;74:1678-1689.
28. Durkop H, Foss HD, Eitelbach F, et al. Expression of the CD30 antigen in non-lymphoid tissues and cells. J Pathol. 2000;190:613-618.